AstraZeneca will market the therapy as Lokelma, while Sun Pharma will promote and distribute it as Gimliand. AstraZeneca will continue to retain the intellectual property rights for SZC. Shares of Astrazeneca Pharma India Ltd ended at ₹9,132.00, down by ₹23.10, or 0.25%, on the BSE.
